Methylphenidate poisoning: An evidence-based consensus guideline for out-of-hospital management

References

• Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279: 1100–1107
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002; 41: 514–521
   PubMed Web of Science ®Google Scholar
• Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006; 163: 579–585
   PubMed Web of Science ®Google Scholar
• Okie S. ADHD in adults. N Engl J Med 2006; 354: 2637–2641
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Reid N, Youniss J, Flanagan A, Wruk KM. 2004 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23: 589–666
   PubMed Web of Science ®Google Scholar
• Drug Facts and Comparisons. Wolters Klewer Health, St. Louis, MO 2006
   Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155: 1325–1331
   PubMed Web of Science ®Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration. Behav Brain Res 1998; 94: 127–152
   PubMed Web of Science ®Google Scholar
• Breggin PR. Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. Int J Risk Saf Med 1999; 12: 3–35
   Google Scholar
• Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry 2003; 42: 288–294
   PubMed Web of Science ®Google Scholar
• Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML. Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics 2005; 115: e749–757
   PubMed Web of Science ®Google Scholar
• Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112: e404
   PubMed Web of Science ®Google Scholar
• Young JG. Methylphenidate-induced hallucinosis: Case histories and possible mechanisms of action. J Dev Behav Pediatr 1981; 2: 35–38
   PubMedGoogle Scholar
• Rothschild CJ, Nicol H. Allergic reaction to methylphenidate. Can Med Assoc J 1972; 106: 1064
   PubMed Web of Science ®Google Scholar
• Feldman H, Crumrine P, Handen BL, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989; 143: 1081–1086
   PubMedGoogle Scholar
• Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001; 24: 99–102
   PubMed Web of Science ®Google Scholar
• Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445–1448
   PubMed Web of Science ®Google Scholar
• Brown CS. Treatment of attention-deficit hyperactivity disorder - a critical review. DICP Ann Pharmacother 1991; 25: 1207–1213
   PubMedGoogle Scholar
• Coffey B, Shader RI, Greenblatt DJ. Pharmacokinetics of benzodiazepines and psychostimulants in children. J Clin Psychopharmacol 1983; 3: 217–225
   PubMed Web of Science ®Google Scholar
• Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37: 457–470
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004; 18: 243–250
   PubMed Web of Science ®Google Scholar
• Dexmethylphenidate (Focalin) for ADHD. Med Lett Drugs Ther. 2002; 44: 45–46
   PubMed Web of Science ®Google Scholar
• Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 14th. Lexi-Comp, Hudson, OH 2006
   Google Scholar
• Hansten PD, Horn JR. Hansten and Horn's drug interactions analysis and management. Facts and Comparisons, St. Louis 2006
   Google Scholar
• Drug Interaction Facts. Facts and Comparisons, St Louis 2006
   Google Scholar
• Sherman M, Hauser GC, Glover BH. Toxic reactions to tranylcypromine. Am J Psychiatry 1964; 120: 1019–1021
   PubMed Web of Science ®Google Scholar
• Feinberg SS. Combined stimulants with monoamine oxidase inhibitors: A review of uses and one possible additional indication. J Clin Psychiatry 2004; 65: 1520–1534
   PubMed Web of Science ®Google Scholar
• Gara L, Roberts W. Adverse response to methylphenidate in combination with valproic acid. J Child Adolesc Psychopharmacol 2000; 10: 39–43
   PubMed Web of Science ®Google Scholar
• Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos 2000; 28: 620–624
   PubMed Web of Science ®Google Scholar
• Coetzee M, Kaminer Y, Morales A. Megadose intranasal methylphenidate (Ritalin) abuse in adult attention deficit hyperactivity disorder. Subst Abus 2002; 23: 165–169
   PubMedGoogle Scholar
• Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002; 14: 219–223
   PubMed Web of Science ®Google Scholar
• Lewman LV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol 1972; 3: 67–70
   PubMed Web of Science ®Google Scholar
• Massello W, 3rd, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci 1999; 44: 220–221
   PubMed Web of Science ®Google Scholar
• Raskind M, Bradford T. Methylphenidate (Ritalin) abuse and methadone maintenance. Dis Nerv Syst 1975; 36: 9–12
   PubMedGoogle Scholar
• Teter CJ, McCabe SE, Boyd CJ, Guthrie SK. Illicit methylphenidate use in an undergraduate student sample: Prevalence and risk factors. Pharmacotherapy 2003; 23: 609–617
   PubMed Web of Science ®Google Scholar
• Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281: 1900–1905
   PubMed Web of Science ®Google Scholar
• Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: A proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493–498
   PubMed Web of Science ®Google Scholar
• Medical Toxicology. 3rd, RC Dart. Lippincott Williams & Wilkins, Philadelphia 2004; 1051–1062
   Google Scholar
• Clinical Toxicology, MD Ford, KA Delaney, LJ Ling, T Erickson. WB Saunders, Philadelphia 2001
   Google Scholar
• Goldfrank's Toxicologic Emergencies. 7th, LR Goldfrank, NE Flomenbaum, NA Lewin, MA Howland, RS Hoffman, LS Nelson. McGraw-Hill, New York 2002
   Google Scholar
• Clinical Management of Poisoning and Drug Overdose. 3rd, LM Haddad, MW Shannon, JF Winchester. WB Saunders, Philadelphia 1998
   Google Scholar
• Poisoning & Drug Overdose. 4th, KR Olson. McGraw-Hill, New York 2004
   Google Scholar
• Methylphenidate management. Poisindex system, RK Klasco. Thomson Micromedex, Greenwood Village, CO March, 2006, edition expires
   Google Scholar
• Kratochvil CJ, Greenhill LL, March JS, Burke WJ, Vaughan BS. The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs 2004; 18: 957–966
   PubMed Web of Science ®Google Scholar
• Bailey B, Letarte A, Abran MC. Methylphenidate unintentional ingestion in preschool children. Ther Drug Monit 2005; 27: 284–286
   PubMed Web of Science ®Google Scholar
• Foley R, Mrvos R, Krenzelok EP. A profile of methylphenidate exposures. J Toxicol Clin Toxicol 2000; 38: 625–630
   PubMed Web of Science ®Google Scholar
• Kim ME, Oderda GM, Klein-Schwatrz W. Toxicity of methylphenidate ingestions in children [abstract]. Vet Hum Toxicol 1989; 31: 371
   Google Scholar
• Marquardt KA, Alsop JA, Lamb JP, Lai C, Walsh MJ, Albertson TE. Methylphenidate ingestions: Comparison of drug formulations [abstract]. J Toxicol Clin Toxicol 2004; 42: 728
   Google Scholar
• White SR, Yadao CM. Characterization of methylphenidate exposures reported to a regional poison control center. Arch Pediatr Adolesc Med 2000; 154: 1199–1203
   PubMed Web of Science ®Google Scholar
• The Harriet Lane Handbook: A Manual for Pediatric House Officers. 17, J Robertson, N Shilkofski. Mosby, Philadelphia 2005; 879
   Google Scholar
• Wender PH, Reimherr FW, Wood D, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142: 547–552
   PubMed Web of Science ®Google Scholar
• Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993; 91: 1101–1106
   PubMed Web of Science ®Google Scholar
• Aman MG, Kern RA, McGhee DE, Arnold LE. Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. J Am Acad Child Adolesc Psychiatry 1993; 32: 851–859
   PubMed Web of Science ®Google Scholar
• Arnold LE, Christopher J, Huestis R, Smeltzer DJ. Methylphenidate vs. dextroamphetamine vs. caffeine in minimal brain dysfunction: Controlled comparision by placebo washout design with Bayes' analysis. Arch Gen Psychiatry 1978; 35: 463–473
   PubMed Web of Science ®Google Scholar
• Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: Systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184–192
   PubMed Web of Science ®Google Scholar
• Biederman J, Quinn D, Weiss M, Markabi S, Weideman M, Edson K, Karlsson K, Pohlmann H, Wigal S. Efficacy and safety of Ritalin® LA™, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003; 5: 833–841
   PubMedGoogle Scholar
• Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004; 43: 559–567
   PubMed Web of Science ®Google Scholar
• Dirksen SJ, D'Imperio JM, Birdsall D, Hatch SJ. A postmarketing clinical experience study of Metadate® CD. Curr Med Res Opin 2002; 18: 371–380
   PubMed Web of Science ®Google Scholar
• Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: Double blind, crossover trial. Pediatrics 1997; 100: 662–666
   PubMed Web of Science ®Google Scholar
• Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: A double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998; 8: 13–25
   PubMed Web of Science ®Google Scholar
• Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30: 245–255
   PubMed Web of Science ®Google Scholar
• Kelly RP, Yeo KP, Teng CH, Smith BP, Lowe S, Soon D, Read HA, Wise SD. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. J Clin Pharmacol 2005; 45: 851–855
   PubMed Web of Science ®Google Scholar
• Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995; 96: 320–325
   PubMed Web of Science ®Google Scholar
• Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin® LA™ and Concerta®) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003; 5: 545–555
   PubMedGoogle Scholar
• McBride MC. An individual double blind crossover trial for assessing methylphenidate response in children with attention deficit disorder. J Pediatr 1988; 113: 137–145
   PubMed Web of Science ®Google Scholar
• Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, Brown R, Xiong X, Wu S, Gururangan S, Reddick WE. Short-term efficacy of methylphenidate: A randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 2004; 22: 4743–4751
   Google Scholar
• Oesterheld JR, Kofoed L, Tervo R, Fogas B, Wilson A, Fiechtner H. Effectiveness of methylphenidate in Native American children with fetal alcohol syndrome and attention deficit/hyperactivity disorder: A controlled pilot study. J Child Adolesc Psychopharmacol 1998; 8: 39–48
   PubMed Web of Science ®Google Scholar
• Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62: 1266–1274
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Quinn PO, Bradbard G, Riddle KD, Brooks E. Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. Arch Gen Psychiatry 1974; 30: 789–793
   PubMed Web of Science ®Google Scholar
• Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 2002; 36: 1142–1149
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The COMACS study). Pediatrics 2004; 113: E206–E216
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J, Lerner M, Concerta Study G. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder - Results from a one-year follow-up study. J Clin Psychopharmacol 2004; 24: 36–41
   PubMed Web of Science ®Google Scholar
• Winsberg BG, Press M, Bialer I, Kupietz S. Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children. Pediatrics 1974; 53: 236–241
   PubMed Web of Science ®Google Scholar
• Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001; 165: 1475–1488
   PubMed Web of Science ®Google Scholar
• Talbot JS, Ahuja AS. Near-fatal methylphenidate misuse. Br J Psychiatry 2001; 178: 278
   PubMed Web of Science ®Google Scholar
• Klein-Schwartz W. Pediatric methylphenidate exposures: 7-year experience of poison centers in the United States. Clin Pediatr (Phila) 2003; 42: 159–164
   PubMed Web of Science ®Google Scholar
• Levine B, Caplan YH, Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986; 10: 209–210
   PubMed Web of Science ®Google Scholar
• American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC). Circulation 2005; 112: 1–5
   Google Scholar
• Keating GM, McClellan K, Jarvis B. Methylphenidate (OROS® formulation). CNS Drugs Jun, 2001; 15: 495–500
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin® LA). Drugs 2002; 62: 2251–2259
   PubMed Web of Science ®Google Scholar